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Abstract Objective The objective of this study was to compare clinical outcomes of pre-
eclamptic pregnancies according to the proteinuria level.
Study Design Secondary analysis of a multicenter prospective cohort study of
women with preeclampsia (PE) symptomatology. Nonproteinuria, mild-proteinuria,
andmassive-proteinuria PEs were deﬁned as: < 165 mg in 12 hours or < 300 mg in 24
hours, 165 mg to 2.69 g in 12 hours or 300 mg to 4.99 g in 24 hours, and  2.7 g in 12
hours or  5.0 g in 24 hours, respectively. Individual and composite maternal, fetal,
and neonatal outcomes were compared among the PE groups.
Results Of the406analyzedpregnancies, 36 (8.8%)hadmassive-proteinuriaPE, 268 (66.0%)
mild-proteinuria PE, and 102 (25.1%) nonproteinuria PE. Compared with the other groups,
massive-proteinuriaPEwomenhadsigniﬁcantlyhigherbloodpressures(p < 0.001),epigastric
pain (p ¼ 0.007), anduricacid serumlevels (p < 0.001)prior todelivery.Compositematernal
morbidity was similar across the groups. Delivery < 340/7 weeks occurred in 80.6, 49.3, and
22.5% of massive-proteinuria, mild-proteinuria, and nonproteinuria PE groups, respectively
(p < 0.0001).Compositeadverseneonataloutcomesweresigniﬁcantlyhigher in themassive-
proteinuria PE compared with the other groups (p ¼ 0.001).
Conclusion While potentially not important diagnostically, massive proteinuria is
associated with more severe clinical manifestations of PE prompting earlier delivery.
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Preeclampsia (PE) affects approximately 3 to 5% of the
pregnant population and is a leading cause of maternal
and perinatal morbidity and mortality.1 One-quarter of
medically indicated preterm deliveries are linked to PE.2 In
the past decades, a progressively increasing prevalence of PE
has been attributed to multiple risk factors including a
signiﬁcant rise in maternal obesity and diabetes,3–5 delayed
childbearing and to an increased rate ofmultiple gestations.6
Women who develop PE are at signiﬁcant risk of early
cardiovascular disease, hypertension, cerebrovascular acci-
dents, and death.7–9 Furthermore, there is growing evidence
that offspring born to preeclamptic women are at increased
risk for early onset of cardiovascular disease and stroke
during adulthood.10,11 That risk seems to be more substan-
tial when PE is diagnosed before 34 weeks of gestation.11
In 2002, the American College of Obstetricians and Gy-
necologists (ACOG) practice bulletin12 recommended follow-
ing the diagnostic criteria of PE established by the National
High Blood Pressure Education Program Working Group in
2000.13 This group deﬁned PE as new onset of hypertension:
systolic blood pressure (SBP)  140 mm Hg or diastolic BP
(DBP)  90 mm Hg after 20 weeks in a previously normo-
tensive woman and proteinuria along with a protein excre-
tion of  0.3 g in a 24-hour period.13 Women with
proteinuria  5 g in a 24-hour specimen or  3þ on two
random urine samples collected at least 4 hours apart met
criteria for severe disease by the 2002 ACOG criteria.12 In
2013, ACOG published new recommendations on hyperten-
sion in pregnancy elaborated by a multidisciplinary panel of
experts.14 Important changes to the PE deﬁnitionwere made
including elimination of the severe PE diagnosis in pregnan-
cies with gestational hypertension and a proteinuria level
of  5 g in 24 hours.14 The rationale behind this new deﬁni-
tion was convincing evidence demonstrating a lack of asso-
ciation between the level of urinary protein (UP) loss and
pregnancy outcomes.14 According to ACOG, the amount of
proteinuria or change in the amount of proteinuria, as
isolated factors, does not justify delivery in preeclamptic
pregnancies with a gestational age (GA) < 370/7 weeks.14
In the new criteria, ACOG recommends diagnosing PE in
the absence of proteinuriawhen any of several abnormalities
are present: thrombocytopenia (platelet count < 100,000/
µL), elevated levels of liver transaminases twice or more
above the normal concentrations, elevated serum creatinine
> 1.1 mg/dL or a doubling elevation in absence of other renal
disease, pulmonary edema, or new-onset cerebral or visual
disturbances.14 Furthermore, “severe features of PE” is diag-
nosed when any of these ﬁndings are present or when
maternal SBP is  160 mm Hg or DBP  110 mm Hg on
two occasions at least 4 hours apart while the patient is
on bed rest.14Maternal/fetal conditions and GA are the most
important factors in determining the timing of delivery of
women with severe disease. For those pregnancies with
stable maternal and fetal conditions and GA < 340/7 weeks,
expectant management that involves daily maternal and
fetal surveillance is recommended at medical centers
equipped with adequate maternal and neonatal intensive
care resources.14
The relationship between heavy proteinuria and adverse
clinical events in pregnancies complicated by PE has been
investigated in multiple studies.15–23 Some studies have
shown that the level of proteinuria is not associated with
adverse maternal15–18,20 or perinatal outcomes.15–20 How-
ever, others have reported that heavy proteinuria increases
both maternal and perinatal morbidities including severe
hypertension, preterm delivery, cesarean delivery, small for
GA (SGA) infants, maternal symptoms, and perinatal mor-
tality rate.21–25 These conﬂicting results likely reﬂect limita-
tions of previous studies including retrospective design,15
proteinuria quantiﬁcation by qualitative dipstick
method,16–18 performance in single-care settings,17,22,23
and inclusion of hypertensive disorders other than PE to
examine pregnancy outcomes.19 Given the recent revision of
the diagnostic criteria for PE, we believe it is appropriate to
reconsider the association between the degree of proteinuria
with the clinical course and pregnancy outcome of PE.
PE Triage by Rapid Assay (PETRA) of novel biomarkers of
placental function and maternal adaptation was a recent
multicenter prospective cohort study that enrolled women
with any signs or symptoms of PE. The primary objective of
this study was to validate the Triage placental growth factor
test as an aid in the diagnosis of PE in symptomatic women.
Importantly, this study classiﬁed PE using the most recent
ACOG’s clinical criteria. The ﬁnal diagnosis was adjudicated
by a panel of independent experts allowing us to compare
pregnancy outcomes between nonproteinuric and proteinu-
ric PEs. The objective of our study was to determine whether
preeclamptic pregnancies with massive proteinuria, deﬁned
as > 2.7 g in 12 hours or > 5.0 g in 24 hours, have worse
maternal, fetal, or neonatal outcomes compared with those
with mild or nonproteinuria.
Materials and Methods
Weconducted a secondary analysis of themulticenter PETRA
prospective cohort study. In PETRA, pregnant women 16 to
45 years of age at 200/7 to 400/7 weeks of gestationwith signs
or symptoms of PE were enrolled at 24 centers in the United
States and Canada between June 2010 and July 2012. Patients
were excluded if the pregnancy had more than three viable
fetuses, active substance abuse, were on dialysis, received
blood product transfusionwithin the previous 48 hours, had
known or suspected infection with human immunodeﬁ-
ciency virus, hepatitis C virus, hepatitis B virus, or other
infectious hepatitis. We also excluded women with under-
lying renal disease. This study was approved by the Institu-
tional Review Board at our institution.
Signs or symptoms of PE that warranted initial evaluation
were new onset of hypertension deﬁned as SBP  140 mm
Hg or DBP  90 mm Hg or rise of SBP  30 mm Hg or
DBP  15 mm Hg from patient’s BP baseline; worsening BP
in patients with chronic hypertension; proteinuria deﬁned
as  1þ dipstick,  0.30 UP/creatinine ratio (UP/CR), or
 300 mg in 24 hours. Symptoms potentially associated
with PE included persistent epigastric or right upper abdom-
inal pain, nausea, vomiting, or headaches/visual
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disturbances; excessive weight gain  5 pounds per week;
laboratory abnormalities such as thrombocytopenia (plate-
lets < 100,000/µL), aspartate aminotransferase (AST), and
alanine transaminase (ALT) twice normal, serum creatinine
> 1.1 mg/dL or having doubled, uric acid > 6.0 mg/dL;
unexplained clinical events including oliguria, pulmonary
edema, and seizure; fetal growth restriction deﬁned as
sonographic estimated fetal weight (EFW)  10th percentile
for GA; and suspected fetal/placental hydrops, uterine artery
Doppler notching, or placental abruption.
At enrollment, demographic and baseline characteristics
such as maternal age, gravity and parity, race,  30 kg/m2
body mass index, PE in previous pregnancies, history of
lupus, history of antiphospholipid antibody syndrome, and
smoking status were recorded. GAwas assigned by a certain
regular last menstrual period (LMP) conﬁrmed by the ear-
liest ultrasound exam. Estimated date of conﬁnement (EDC)
was assigned by the earliest ultrasound in women with
irregular menstrual cycles or an uncertain LMP. The earliest
ultrasound instead of LMP was used for EDC assignment if
discrepancies existed as:  5 days for a ﬁrst trimester
(60–136 weeks) ultrasound,  10 days for an early second
trimester (140–226) ultrasound,  14 days for a late second
trimester (230–276) ultrasound, and  21 days for a third
trimester (280 to term) ultrasound. BP was obtained follow-
ing ACOG’s recommendations.12 Laboratory evaluations in-
cluded hematocrit, platelet count, serum creatinine, ALT,
AST, lactate dehydrogenase (LDH), and uric acid. Women
with proteinuria  1þ on dipstick or UP/CR  0.3 mg/mg
underwent 12-hour or 24-hour urine protein excretion
assessment. Patients without criteria for PE at the initial
study visit whose diagnosis was again suspected at least
1 week later underwent re-evaluation in the same fashion.
Medical management including hospitalization, expectant
management, and delivery was determined by the attending
physicians and internal protocols of the participating
institutions.
Our cohort consisted of women with diagnosis of PE
adjudicated by an independent expert panel following the
most recent guidelines.14HELLP syndromewas deﬁned as PE
plus AST and ALT twice normal, LDH twice normal, and
thrombocytopenia (platelets < 100,000/µL). Preeclamptic
pregnancies were classiﬁed in three groups according to
the degree of proteinuria: (1) nonproteinuria PEwas deﬁned
as either proteinuria < 165 mg in 12 hours or < 300 mg in
24 hours; (2) mild-proteinuria PE included patients with
proteinuria between 165 mg and 2.7 g in 12 hours or from
300 mg to 4.9 g in 24 hours; and (3) massive-proteinuria PE
criteriawere proteinuria > 2.7 g in 12 hours or > 5.0 g in 24
hours. We used 12 hours proteinuria cutoff values that have
been reported to correlate well with 24 hours urine protei-
nuria values in previous studies.26,27 The highest timed
proteinuria valuewas selected in caseswithmultiple testing.
Maternal demographic and clinical characteristics were
compared between the PE groups. BP values, symptomatol-
ogy, and laboratory parameters within 24 hours of delivery
were analyzed in each group. Mode of delivery, timing of
delivery, birth weight, Apgar scores, and arterial cord gas
values were also analyzed when available. Women with
superimposed PE were excluded.
Maternal, fetal, and neonatal outcomes were compared
among the PE subgroups categorized by their degree of
proteinuria. Composite adverse maternal outcome was de-
ﬁned as the presence of any of the following: acute renal
failure, liver hematoma/rupture, acutemyocardial infarction,
cortical blindness, retinal detachment, cerebrovascular acci-
dent, pulmonary edema/adult respiratory distress syn-
drome, placental abruption, eclampsia, need for third
intravenous agent to control BP, disseminated intravascular
coagulation, or maternal death. Composite adverse fetal
outcome included preterm delivery < 340/7 weeks or < 370/
7 weeks, intrauterine growth restriction (IUGR) deﬁned as
EFW < 10th percentile or < 5th percentile by ultrasound
exam, or antepartum/intrapartum fetal death. Composite
adverse neonatal outcome was deﬁned as any of the follow-
ing: respiratory distress syndrome (RDS), any grade of in-
traventricular hemorrhage (IVH), necrotizing enterocolitis,
bronchopulmonary dysplasia, periventricular leukomalacia,
retinopathy of prematurity, seizure, or neonatal intensive
care unit (NICU) admission for > 48 hours for full-term
infant. Diagnosis of neonatal complications was made by
the neonatologists at individual participating sites following
institutional standardized protocols. Chi-square test was
used for analysis of categorical variables and analysis of
variance (ANOVA) was used to compare continuous data.
Fisher’s exact test was used when cells had expected counts
less than 5. The Wilcoxon rank-sum test was used to analyze
differences in the median GA at diagnosis of PE. Post hoc
Tukey’s test was performed after ANOVA when indicated.
Level of signiﬁcance was set at < 0.05. All reported tests of
statistical signiﬁcance were two sided. All analyses were
performed with SAS for Windows (version 9.4).
Results
A total of 675 patients were adjudicated with a ﬁnal diag-
nosis of PE by the PETRA’s independent panel. Of these, 406
women (60.1%) underwent timed 12 or 24 hours urine
collections. One-hundred two women (25.1%) were classi-
ﬁed as nonproteinuria PE, 268 pregnancies (66.0%) hadmild-
proteinuria PE, and 36 cases (8.8%) had massive-proteinuria
PE. Baseline demographic and clinical characteristics were
similar among the three groups, with the exception of
nulliparity which was more prevalent in women with mas-
sive-proteinuria PE (►Table 1). The rate of twin and triplet
gestations was low and not signiﬁcantly different between
the PE groups. Mean UP excretion levels in each group are
depicted in ►Table 1. Massive-proteinuria PE women com-
pared with mild-proteinuria and nonproteinuria PE groups
were enrolled at amuch earlier GA (medianGA ¼ 30.6weeks
[interquartile range, IQR, 28.2–33.6] vs. 32.4 weeks [IQR,
28.2–33.6] and 32.9 weeks [IQR, 30.4–35.6], respectively,
►Table 1; p ¼ 0.002). Mean SBP and DBP within 24 hours
of delivery was signiﬁcantly higher in mass-proteinuria PE
pregnancies compared with those with mild and no protei-
nuria (p < 0.001; ►Table 1).
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Platelet count and liver enzymes serum levels were simi-
lar among the groups. The uric acid levels were higher in the
massive-proteinuria PE (median, 6.7 mg/dL; IQR, 5.5–7.6)
compared with the mild-proteinuria PE (median, 5.9 mg/dL;
IQR, 4.9–7.0) and nonproteinuria PE (median, 5.1mg/dL; IQR,
4.3–5.8) groups (p < 0.001; ►Table 2). Uric acid was also
signiﬁcantly higher in the mild-proteinuria PE compared
with nonproteinuria PE pregnancies. Among clinical signs
and symptoms related to PE (►Table 3), RUQ/epigastric pain
was reported in 19.4% of massive-proteinuria PE women
Table 1 Demographic and clinical characteristics of women with PE stratiﬁed by protein quantity in urine
Nonproteinuria Mild proteinuria Massive
proteinuria
p-Value
N ¼ 102 % N ¼ 268 % N ¼ 36 %
Plurality
Singletons 96 245 32 0.82
Multiples 6 23 4
Twins 5 20 2
Triplets 1 3 2
Age (y)
16–24 28 27.5 90 33.6 13 36.1 0.76
25–34 54 52.9 130 48.5 18 50.0
35–45 20 19.6 48 17.9 5 13.9
Gravidity
Nulliparous 53 52.0 168 62.7 29 80.6 0.003
Multiparous 49 48.0 100 37.3 7 19.4
Race
White 58 56.9 147 54.9 23 63.9 0.70
Black 30 29.4 87 32.5 7 19.4
Asian 3 2.9 5 1.9 1 2.8
Other 11 10.8 29 10.8 5 13.9
Median GA at enrollment (wk; IQR) 32.9 (30.4–35.6) 32.4 (29.7–34.9) 30.6 (28.2–33.6) 0.002a
BMI  30 63 61.8 169 63.1 21 58.3 0.94
Tobacco use
Present 79 77.5 227 84.7 28 77.8 0.18
Quit 23 22.5 41 15.3 8 22.2
H/O preexisting diabetes 9 8.8 14 5.2 2 5.6 0.75
H/O lupus 0 0 2 0.7 1 2.8 0.38
H/O APS 0 0 1 0.4 0 0 0.26
H/O PE in a previous gestation 37 36.3 77 28.7 7 19.4 0.26
Mean SBPb (mean  SD) 143.3  12.1 145.7  11.6 148.3  8.9 < 0.001a
Mean DBPb (mean  SD) 84.2  8.8 86.7  7.8 88.6  8.0 < 0.001a
Highest SBPc (mean  SD) 168.1  20.7 171.5  18.2 175.4  16.1 0.0008d
Highest DBPc (mean  SD) 101.9  13.5 103.4  10.9 108.3  16.7 0.006a
24-h proteinuria (mg; mean  SD) 162.9  74.5 1,170  1,149 9,117  4,722 0.0001e
12-h proteinuria (mg; mean  SD) 117.0  41.0 793.9  734.7 6,015  976.6 0.0001d
Abbreviations: APS, antiphospholipid antibody syndrome; BMI, body mass index early in gestation; DBP, diastolic blood pressure; GA, gestational
age; H/O, history of; IQR, interquartile range; PE, preeclampsia; SBP, systolic blood pressure; SD, standard deviation.
aSigniﬁcant difference between massive-proteinuria PE and the other PE groups.
bMean blood pressures within 24 hours before delivery.
cHighest blood pressure before delivery.
dSigniﬁcant difference between non-proteinuria PE and the other PE groups.
eSigniﬁcant difference in all multiple comparisons between the PE groups.
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compared with 5.2% in mild-proteinuria PE and 7.8% of
nonproteinuria PE patients (p ¼ 0.007; signiﬁcant difference
between mild- and massive-proteinuria PEs). Maternal neu-
rological symptoms did not vary signiﬁcantly between the PE
subgroups. HELLP syndrome was diagnosed in 2/36 (5.6%) of
massive-proteinuria PE, in 1/268 (0.4%) of mild-proteinuria
PE, and in 4/102 (3.9%) of those with nonproteinuria PE.
HELLP syndrome rate was signiﬁcantly lower in the mild-
proteinuria PE group compared with the other groups
(p < 0.005), but similar between nonproteinuria and mas-
sive-proteinuria PEs.
There was not a signiﬁcant difference in either individual
or composite adverse maternal morbidity among the PE
groups (►Table 4). Adverse maternal morbidity was uncom-
mon overall, with any element occurring in < 6% of cases in
all three groups. There were no cases of maternal death.
Median GA (IQR) at delivery for massive-proteinuria, mild-
proteinuria, and nonproteinuria PE groups were 31.3 (28.6–
33.6), 34.0 (30.6–36.7), and 36.6 (34.1–38.4) weeks, respec-
tively (►Table 5; p < 0.001). Preterm delivery < 340/7 weeks
occurred in 80.6% of massive-proteinuria PE patients, in
49.3% of mild-proteinuria PEwomen, and in 22.5% of women
with nonproteinuria PE (p < 0.0001). The difference in the
preterm birth rate < 340/7 weeks between the nonprotei-
nuria and mild-proteinuria PE groups was also signiﬁcant
(p < 0.0001). Similar differences were noted in the delivery
rate < 370/7 weeks across all the groups (►Table 5). Cesarean
delivery rate was signiﬁcantly higher in the massive-protei-
nuria PE (86.1%) than in the mild-proteinuria PE (64.9%) and
nonproteinuria PE (55.9%) groups (p ¼ 0.0001). Stillbirth and
IUGR (both, EFW < 10th percentile or EFW < 5th percentile
by ultrasound exam) rates were similar across the groups
(►Table 5). Composite adverse fetal outcome was driven by
the signiﬁcant differences noted in the pretermdelivery rates
among the groups, with the highest percentages noted, as
mentioned earlier, in the massive-proteinuria PE group.
Of our study’s 443 neonates, 42 (9.4%) were born to
massive-proteinuria, 292 (66.0%) to mild-proteinuria, and
109 (24.6%) to nonproteinuria PEwomen. Mean birth weight
was signiﬁcantly lower in the massive-proteinuria PE neo-
nates (1,392  557 g) compared with those born to mild-
proteinuria PE (1,937  892 g) and nonproteinuria
(2,456  885 g) PE women (p < 0.001). The differences in
birth weight were also signiﬁcant between nonproteinuria
and mild-proteinuria PE neonates (►Table 6). Apgar score
< 7 at 5 minutes was reported more commonly in the
massive-proteinuria PE infants (19.0%) than for mild-protei-
nuria (7.2%) and nonproteinuria (6.4%) groups, respectively
(p ¼ 0.0005). Umbilical arterial cord gasses were reported
only in 226 of 443 subjects (51.0%) and there was no
difference on the mean pH or in the number of pH values
< 7.0 across the groups. RDSwas themost common neonatal
complication affecting 47.6% of massive-proteinuria PE,
28.8% of mild-proteinuria PE, and 11.0% of non-proteinuria
Table 2 Laboratory parameters within 24 hours of delivery in the PE subgroups
Nonproteinuria Mild proteinuria Massive proteinuria p-Value
N ¼ 102 Median (IQR) N ¼ 268 Median (IQR) N ¼ 36 Median (IQR)
Platelets (N/µL) 95 207.0
(160.0–258.0)
223 202.0
(161.0–246.0)
33 196.0 (153.0–228.0) 0.33
AST (U/L) 87 21.0
(17.0–32.0)
210 21.0
(17.0–31.0)
31 24.0 (20.0–34.0) 0.16
ALT (U/L) 86 16.0 (12.0–27.0) 205 17.0
(12.0–28.0)
31 18.0 (14.0–34.0) 0.54
Serum creatinine
(mg/dL)
86 0.6 (0.5–0.7) 210 0.6
(0.5–0.7)
34 0.7 (0.6–0.8) < 0.01a
Uric acid (mg/dL) 62 5.1 (4.3–5.8) 154 5.9
(4.9–7.0)
22 6.7 (5.5–7.6) < 0.001b
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; IQR, interquartile range; PE, preeclampsia.
aSigniﬁcant difference between massive-proteinuria PE compared with mild-proteinuria PE and nonproteinuria PE.
bSigniﬁcant difference in all multiple comparisons between the groups.
Table 3 PE-related symptoms between the PE subgroups
Nonproteinuria Mild proteinuria Massive
proteinuria
p-Value
N ¼ 102 % N ¼ 268 % N ¼ 36 %
RUQ pain/epigastric pain 8 7.8 14 5.2 7 19.4 0.007a
Headache, visual changes 34 33.3 104 38.8 16 44.4 0.79
Nausea and vomiting 8 7.8 25 9.3 6 16.7 0.29
Abbreviations: PE, preeclampsia; RUQ, right upper quadrant.
aSigniﬁcant difference between massive-proteinuria and mild-proteinuria PE groups.
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PE newborns (p < 0.001;►Table 7). Other individual adverse
neonatal outcomes did not differ among the groups. How-
ever, composite adverse neonatal outcome, driven mainly by
RDS and other prematurity-related complications, was sig-
niﬁcantly higher in the massive-proteinuria PE than in the
other groups (p ¼ 0.001; ►Table 7). There were no neonatal
deaths in any group.
Comment
This prospective cohort study with independent adjudica-
tion of PE diagnosis using the new 2013 ACOG criteria
indicates that individual and composite adverse maternal
outcomes were not increased in preeclamptic women with
massive proteinuria compared with those with mild or
nonproteinuria PE. However, we found that massive-protei-
nuria PEwas associatedwith pretermdelivery < 340/7weeks
in more than 80% of cases, whichwas almost twice as high as
the mild-proteinuria PE group and almost four times higher
than in the nonproteinuria group. Women with massive-
proteinuria had more PE-related symptoms and laboratory
abnormalities including higher BP, RUQ/epigastric pain, and
higher uric acid levels suggesting a more severe clinical
presentation. Also, enrollment occurred much earlier in
women with massive proteinuria indicating that the diag-
nosis was made at more preterm GAs. This earlier and more
Table 5 Individual and composite adverse fetal outcomes in women with PE stratiﬁed by protein quantity in urine
Nonproteinuria Mild proteinuria Massive proteinuria p-Value
Pregnancies N ¼ 102 % N ¼ 268 % N ¼ 36 %
Fetuses N ¼ 109 % N ¼ 294 % N ¼ 42 %
Median GA at delivery
(wk; IQR)
36.6 (34.1–38.4) 34.0 (30.6–36.7) 31.3 (28.6–33.6) < 0.001a
Delivery < 340/7 wk 23 22.5 132 49.3 29 80.6 < 0.0001a
Delivery < 370/7 wk 66 64.7 190 70.9 31 86.1 0.001a
Stillbirth 0 0 2 0.7 0 0 N/A
EFW < 10th percentile 11 10.1 30 10.2 4 9.5 0.99
EFW < 5th percentile 4 3.7 15 5.1 2 4.8 0.83
Composite adverse fetal
outcome
64 58.7 228 77.6 40 95.2 < 0.0001a
Abbreviations: EFW, estimated fetal weight; GA, gestational age; IQR, interquartile range; PE, preeclampsia.
aSigniﬁcant difference noted in all multiple comparisons between the PE groups.
Table 4 Individual and composite adverse maternal outcome in women with PE stratiﬁed by protein quantity in urine
Nonproteinuria Mild proteinuria Massive
proteinuria
p-Value
N ¼ 102 % N ¼ 268 % N ¼ 36 %
Acute renal failure 0 0 0 0 1 2.8 0.094
Liver hematoma/rupture 0 0 0 0 0 0 N/A
Acute myocardial infarction 0 0 0 0 0 0 N/A
Cortical blindness 0 0 0 0 0 0 N/A
Renal detachment 0 0 0 0 0 0 N/A
Pulmonary edema/ARDS 3 2.9 4 1.5 1 2.8 0.06
Placental abruption 0 0 5 1.9 1 2.8 0.09
Death 0 0 0 0 0 0 N/A
Eclampsia 0 0 0 0 1 2.8 0.09
Third IV antihypertensive agent 1 1.0 8 3.0 0 0 0.11
DIC 0 0 0 0 1 2.8 0.09
Composite adverse maternal outcome 4 3.9 9 3.4 2 5.6 0.70
Abbreviations: ARDS, acute respiratory distress syndrome; DIC, disseminated intravascular disease; IV, intravenous; N/A, not available; PE,
preeclampsia.
Note: Fisher’s exact tests were used when several cells have expected counts less than 5.
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severe presentation certainly inﬂuenced the clinical man-
agement and the ﬁnal decision for delivery. The higher
neonatal morbidity rate seen in infants born to massive-
proteinuria women was most likely related to the earlier GA
at delivery with RDS being the most common neonatal
complication affecting almost half of these infants. The
cesarean delivery rate was extremely high (86.1%) in the
massive-proteinuria PEgroup and 19% of newborns from this
group had Apgar scores < 7 at 5 minutes. Although we did
not analyze fetal testing data, our results suggest the possi-
bility that compromise of the fetal condition played a major
role in the mode and timing of delivery in these patients.
IUGR, deﬁned as EFW < 10th percentile, occurred in 9.5 to
10.2% of the enrolled pregnancies without signiﬁcant differ-
ences among the groups.
Several studies have shown that the presence of protei-
nuria in PE increases the risk for speciﬁc adverse pregnancy
outcomes.21–25 Using a different proteinuria threshold from
our study, a recent secondary analysis of the Vitamins in PE
(VIP) trial found that preeclamptic pregnancies with a timed
24-hour proteinuria  500 mg compared with 300 to
499 mg delivered signiﬁcantly earlier (33.2 vs. 37.2 weeks)
and had a signiﬁcantly higher cesarean delivery rate (78 vs.
48%).21 In the VIP trial, preterm delivery < 34 weeks oc-
curredmore often in the groupwith greater proteinuria (26.7
vs. 13.3%). Two prospective cohorts have shown that the
presence of proteinuria, deﬁned as UP/CR  30 mg/mmol,25
or > 300 mg in 24 hours,22,25 compared with nonprotei-
nuria in preeclamptic pregnancies is associated with both
increased maternal and fetal complications such as hyper-
uricemia, severe hypertension, renal insufﬁciency, throm-
bocytopenia, liver disease, preterm delivery < 370/7 weeks,
perinatal mortality, and SGA.22,25 Other investigators have
found that elevated UP excretion assessed by spot UP/CR (
0.3 mg/mg) also predisposes to adverse maternal and peri-
natal outcomes including severe maternal hypertension,
Table 6 Birth outcomes in PE pregnancies stratiﬁed by protein quantity in urine
Nonproteinur-
ia
Mild proteinuria Massive
proteinuria
p-Value
Cesarean delivery, N (%) 57 (55.9) 174 (64.9) 31 (86.1) 0.0001a
Birth weight (g; mean  SD) 2,456  885.3 1,937  892.8 1,392  557.0 < 0.001a
Neonatal gender N % N % N %
Female 61 56.0 162 55.5 24 57.1 0.60
Male 48 44.0 130 44.2 18 42.9
Apgar score < 7 at 5 min 7 6.4 21 7.2 8 19.0 0.0005b
Umbilical cord arterial pH < 7.0c 1 0.9 1 0.3 0 0 0.40
Abbreviations: GA, gestational age; PE, preeclampsia; SD, standard deviation.
aSigniﬁcant difference in all multiple comparisons between the PE groups.
bSigniﬁcant difference between massive-proteinuria and the other PE groups.
cData available in 226 cases.
Table 7 Individual and composite adverse neonatal outcome in women with PE stratiﬁed by protein quantity in urine
N ¼ 443 Nonproteinuria Mild proteinuria Massive
proteinuria
p-Value
N ¼ 109 % N ¼ 292 % N ¼ 42 %
Respiratory distress syndrome 12 11.0 84 28.8 20 47.6 < 0.001a
Intraventricular hemorrhageb 3 2.8 13 4.5 3 7.1 0.44
Necrotizing enterocolitis 1 0.9 4 1.4 0 0 0.72
Bronchopulmonary dysplasiab 0 0 2 0.7 2 4.8 0.10
Periventricular leucomalacia 0 0 0 0 0 0 N/A
Retinopathy of prematurityb 2 1.8 7 2.4 4 9.5 0.10
Seizure 0 0 0 0 0 0 N/A
NICU admission > 48 h for full-term infant 2 1.8 0 0 0 0 N/A
Neonatal death 0 0 0 0 0 0 N/A
Composite adverse neonatal outcome 17 15.6 94 32.0 21 50.0 0.001a
Abbreviations: N/A, not available; NICU, neonatal intensive care unit; PE, preeclampsia..
aSigniﬁcant difference in all multiple comparisons between the PE groups.
bFisher’s exact tests were used when several cells have expected counts less than 5.
American Journal of Perinatology Reports Vol. 7 No. 1/2017
Massive Urinary Protein Excretion in Preeclampsia Mateus et al. 55
increased liver enzymes, neurological symptoms, admission
to intensive care unit, eclampsia, cesarean delivery, preterm
birth, and low birthweight.23,24One of these studies showed
that high maternal UP/CR was also associated with low
Apgar scores and perinatal death.23 Recent multicenter pro-
spective studies conducted in low- and middle-income
countries have developed and validated clinical prediction
models for adverse maternal outcomes and perinatal death
among pregnancies with hypertensive disorders (miniPIERS
[Preeclampsia Integrated Estimate of Risk]). In those studies,
dipstick proteinuriawas included in themodels as one of the
predictors for these adverse outcomes.28,29
Conversely, other evidence does not support the associa-
tion between proteinuria and adverse pregnancy out-
comes.15–20 The most comprehensive study is a systematic
review of 16 primary studies conducted in 2009.18 This
systematic review showed that proteinuria was not asso-
ciated with eclampsia, abruption, or HELLP syndrome, neo-
natal death, perinatal death, SGA, or NICU admission. Only
the stillbirth rate was found to be higher in pregnancies with
heavy proteinuria (positive likelihood ratio, 2.0; 95% con-
ﬁdence interval, 1.5–2.7). That systematic review, however,
did not report associations with other important adverse
outcomes such as preterm birth rate and neonatal morbidity.
Importantly, 5 of the 16 studies (31.2%) were retrospective
and proteinuria quantiﬁcation was performed by dipstick
also in 5 studies. Other limitations included heterogeneity
among the studies in regard to study population, deﬁnition
of PE, and proteinuria thresholds.
One retrospective cohort included in the systematic re-
view had a similar design to our study.15 Perinatal outcomes
were compared between preeclamptic pregnancies with 24-
hour proteinuria < 5, 5 to 9.9, and  10 g. This study re-
ported that maternal outcomes did not differ between the PE
subgroups. The authors found that compared with women
with the lesser amounts of proteinuria (< 5 g/24 hours),
those women with  10 g proteinuria were diagnosed ear-
lier (30.6  3.3 vs. 32.3  3.4 weeks) and had earlier deliv-
eries (30.9  3.3 vs. 33.0  3.2 weeks). Neonatal
complications, that is, RDS and IVH were more common in
infants born to mothers with  10 g/24 hours of proteinuria
compared with the other subsets of patients, but the differ-
ence was not statistically different.
Clinical management of enrolled patients was dictated by
institutional standardized protocols of participating centers
and the ﬁnal decision for delivery was made considering the
global maternal and fetal condition. Composite adverse
maternal outcome occurred in the range of 3 to 6% of all
pregnancies and it was similar across the PE groups. Adher-
ence to clinical protocols including prompt delivery in ter-
tiary centers likely explains the low rate of serious adverse
maternal outcomes, stillbirth, and neonatal mortality in this
cohort. Massive UP excretion > 2.7 g in 12 hours or > 5 g in
24 hours was highly prevalent in pregnancies with early
onset of PE < 34 weeks, a variety of PE typically associated
with the greatest maternal and perinatal risk. Current
clinical obstetrical guidelines in the United States and
Canada recommend the exclusion of massive proteinuria
> 5 g/24 hours14,30 as a marker of clinical severity and
delivery < 370/7 weeks is not indicated if this is the only
detected abnormality. This may be reasonable if massive
proteinuria is an isolated ﬁnding; however, it is frequently
associated with other clinical manifestations and laboratory
abnormalities indicative of greater disease severity and a
higher rate of speciﬁc adverse pregnancy outcomes.
Exclusion of massive proteinuria from the diagnostic
criteria of severe PE could erroneously lead clinicians to
believe that these pregnancies have a low rate of complica-
tions and better outcomes than those now categorized as PE
with “severe features.”14,30 In fact, our subgroup of nonpro-
teinuria PE deﬁned by current ACOG clinical and laboratory
parameters as having severe features had the most favorable
pregnancy outcomes among the studied groups. The median
GA at delivery in this groupwasmore than 4weeks later than
in the massive-proteinuria PE group, the mean birth weight
was signiﬁcantly higher, and the rates of cesarean delivery
and neonatal complications were much lower. Although no
longer part of the clinical criteria for diagnosis, our investi-
gation supports assessment for and observatory vigilance of
pregnancies with massive proteinuria. In deciding to under-
take expectant management for these pregnancies, the
clinician should closely follow a clinical protocol such as
the one outlined in the committee opinion of the Society for
Maternal-Fetal Medicine.31
Our data emphasize the limitations of current and past
classiﬁcations of PE. The complexity of the disease makes it
very challenging to categorize as less or more severe in the
ample clinical spectrum. Until we develop a more accurate
ancillary test that improves our ability to diagnose PE and
predict its outcomes, we should not overlook pregnancies
with massive proteinuria even if it is no longer considered a
component of the diagnostic criteria for severe PE.
The small sample size of themassive-proteinuria PEgroup
is a major limitation of our study. In the original cohort,
proteinuria was measured by different methods including
urine dipstick, UP/CR, and timed 12 and 24 hours urine
collections. Although all possess accuracy limitations, the
latter has been considered the “gold standard” test for several
decades. Several studies have reported that the amount of
proteinuria collected in a shorter period of time (12 hours)
correlates well with the standard 24 hours urine collec-
tion.26,27 We selected these two methods, as they were
considered the most accurate tests available for the quanti-
ﬁcation of proteinuria. Unfortunately, only 406 of the 675
women diagnosed with PE underwent either of these tests.
Our small sample size increases the probability of type II
error in some of our statistical analysis. This is particularly
true for the relatively rare but life-threatening maternal
complications of PE. Also, the small number of cases with
massive proteinuria limits our ability to perform additional
analysis that might identify a proteinuria threshold at which
adverse pregnancy outcomes could become signiﬁcantly
more likely. Although, an independent panel of experts
made the diagnosis of PE using current clinical guidelines
in the United States, we cannot exclude the possibility of
selection bias in this cohort. Relevant clinical data such as
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fetal testing results prior to delivery were not available for
analysis limiting our capacity for explaining the high rate of
preterm birth, cesarean delivery, and high frequency of low
Apgar score in the massive-proteinuria PE group. Further-
more, umbilical cord gasses were only obtained in approxi-
mately half of the neonates.
In summary, our investigation found that massive protei-
nuria occurs frequently in preeclamptic pregnancies diag-
nosed at early GAs and is often associated with more severe
maternal and laboratory abnormalities. We believe that
quantiﬁcation of maternal proteinuria by some method
should continue to be part of the clinical evaluation of PE.
Importantly, massive proteinuria is unlikely to be an isolated
ﬁnding.Whenpresent, a judicious clinical assessment for the
presence of other severe clinical features is justiﬁed. While
some may argue that quantiﬁcation of proteinuria is an
insufﬁcient predictor of severity and may have resulted in
unnecessary early preterm birth, we believe this is unlikely.
This cohort demonstrates the association of massive protei-
nuria with earlier disease onset, severe BP elevations, more
frequent laboratory abnormalities, severe maternal symp-
toms, low Apgar scores, and a higher cesarean delivery rate
suggesting that it is a covariable indicating maternal/fetal
severity rather than a confounding variable. We encourage
the clinician to consider the implications that massive pro-
teinuria has in the clinical course and outcome of PE.
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